Dare Bioscience Q1 2026 Earnings Report

Dare Bioscience EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.33
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Dare Bioscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.03 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Dare Bioscience Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, May 12, 2026
• Conference Call Time: 4:30PM ET

Dare Bioscience (NASDAQ:DARE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market.

Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.